Aspergillosis in Nigeria: A Critical Review of Disease Burden, Diagnostic Capacity and Research Priorities

S. G. Jonathan

Department of Botany, Myco-Pathology & Applied Microbiology Research Group, University of Ibadan, Oyo State, Nigeria.

F. T. Awodiran *

Department of Botany, Plant Physiology and Biochemistry Unit, University of Ibadan, Oyo State, Nigeria.

O. B. Ogunsanwo

Department of Botany, Myco-Pathology & Applied Microbiology Research Group, University of Ibadan, Oyo State, Nigeria.

E. R. Olanipekunt

Department of Botany, Myco-Pathology & Applied Microbiology Research Group, University of Ibadan, Oyo State, Nigeria.

P. N. Ekidiare

Department of Botany, Myco-Pathology & Applied Microbiology Research Group, University of Ibadan, Oyo State, Nigeria.

H. M. Ishola

Department of Botany, Myco-Pathology & Applied Microbiology Research Group, University of Ibadan, Oyo State, Nigeria.

M. A. Imran

Department of Botany, Myco-Pathology & Applied Microbiology Research Group, University of Ibadan, Oyo State, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Aspergillosis comprises biologically and clinically distinct conditions whose significance in Nigeria is difficult to establish because fungal disease is frequently evaluated within pathways designed for tuberculosis, asthma, human immunodeficiency virus (HIV) infection and other disorders. This critical narrative review examines how Nigerian evidence has been generated, which patient groups are most plausibly underserved, how diagnostic limitations shape reported disease frequency, and which research investments are most defensible. Literature published from 2009 to 4 September 2026 was identified through targeted scholarly searches, regional sources, citation tracing and verification against accessible original publications and clinical guidance; earlier foundational work was considered when necessary. National estimates of chronic pulmonary aspergillosis and allergic disease derive largely from models, whereas direct Nigerian observations are concentrated in selected tuberculosis clinics, specialist laboratories and tertiary hospitals. High proportions of chronic pulmonary aspergillosis in enriched clinical cohorts should therefore not be read as national prevalence or as evidence of a temporal epidemic. Invasive aspergillosis remains particularly under-characterised through clinical surveillance. Nigerian serological evaluations suggest that assay thresholds and diagnostic formats are context dependent, while facility surveys and on-site audits demonstrate important gaps in trained personnel, quality assurance and access to mycological testing. Environmental and clinical susceptibility studies provide incomplete, sometimes apparently conflicting signals about triazole resistance; their sampling frames make those findings compatible rather than mutually exclusive. The review proposes a syndrome-specific, tiered diagnostic and surveillance framework linked to tuberculosis and respiratory services, supported by reference laboratories and sentinel antifungal-resistance monitoring. Priorities include prospective multi-site incidence studies, independent diagnostic validation, outcome-based implementation trials, exposure-informed susceptibility surveillance and economic evaluation. Better identification of disease will require both laboratory investment and more rigorous denominators, reference standards and follow-up, rather than extrapolation of isolated institutional findings.

Keywords: Chronic pulmonary aspergillosis, tuberculosis sequelae, invasive fungal disease, Aspergillus immunoglobulin G, diagnostic implementation, triazole resistance, Nigeria


How to Cite

Jonathan, S. G., F. T. Awodiran, O. B. Ogunsanwo, E. R. Olanipekunt, P. N. Ekidiare, H. M. Ishola, and M. A. Imran. 2026. “Aspergillosis in Nigeria: A Critical Review of Disease Burden, Diagnostic Capacity and Research Priorities”. Asian Journal of Biotechnology and Genetic Engineering 9 (2):496-524. https://doi.org/10.9734/ajbge/2026/v9i2211.

Downloads

Download data is not yet available.